Medicine and Dentistry
Cyclophosphamide
100%
Rituximab
100%
Systemic Lupus Erythematosus
83%
Patient
66%
Childhood
66%
Case Report
50%
Follow up
33%
Corticosteroid
33%
Therapeutic Procedure
33%
Complication
16%
Wellbeing
16%
Adverse Event
16%
Toxicity
16%
Serum
16%
Febrile Neutropenia
16%
Prednisone
16%
Immunoglobulin
16%
Immunoglobulin M
16%
Lupus Nephritis
16%
SLEDAI
16%
INIS
cyclophosphamide
100%
lupus
100%
patients
66%
administration
33%
corticosteroids
33%
data
16%
levels
16%
range
16%
toxicity
16%
values
16%
reduction
16%
prednisone
16%
immunoglobulins
16%
nephritis
16%
Immunology and Microbiology
Rituximab
100%
Cyclophosphamide
100%
Systemic Lupus Erythematosus
83%
Childhood
66%
Nephritis
16%
Immunoglobulin M
16%
Prednisone
16%
Wellbeing
16%
Immunoglobulin Blood Level
16%
Reduction (Chemistry)
16%
Lupus Erythematosus
16%
Pharmacology, Toxicology and Pharmaceutical Science
Cyclophosphamide
100%
Rituximab
100%
Systemic Lupus Erythematosus
83%
Corticosteroid
33%
Toxicity
16%
Febrile Neutropenia
16%
Adverse Event
16%
Complication
16%
Prednisone
16%
Immunoglobulin
16%
Immunoglobulin M
16%
Lupus Erythematosus Nephritis
16%
Biochemistry, Genetics and Molecular Biology
Cyclophosphamide
100%
Rituximab
100%
Childhood
66%
Corticosteroid
33%
Taxonomy
33%
Wellbeing
16%
Prednisone
16%
Immunoglobulin Blood Level
16%
Reduction (Chemistry)
16%